| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eosinophilic Esophagitis | 139 | 2025 | 318 | 24.740 |
Why?
|
| Eosinophilia | 84 | 2024 | 204 | 14.280 |
Why?
|
| Enteritis | 43 | 2024 | 93 | 8.560 |
Why?
|
| Eosinophils | 59 | 2024 | 324 | 7.980 |
Why?
|
| Gastritis | 42 | 2024 | 96 | 7.330 |
Why?
|
| Esophagitis | 33 | 2023 | 67 | 6.090 |
Why?
|
| Esophagus | 42 | 2024 | 251 | 5.800 |
Why?
|
| Gastroesophageal Reflux | 27 | 2022 | 232 | 2.930 |
Why?
|
| Colitis | 21 | 2024 | 245 | 2.670 |
Why?
|
| Proton Pump Inhibitors | 18 | 2025 | 100 | 2.530 |
Why?
|
| Esophagoscopy | 29 | 2025 | 198 | 2.520 |
Why?
|
| Intestinal Mucosa | 27 | 2019 | 593 | 2.320 |
Why?
|
| Food Hypersensitivity | 19 | 2024 | 177 | 2.090 |
Why?
|
| Gastrointestinal Diseases | 11 | 2019 | 198 | 1.980 |
Why?
|
| Child | 125 | 2025 | 20962 | 1.820 |
Why?
|
| Epithelial Cells | 18 | 2024 | 1063 | 1.700 |
Why?
|
| Gastrointestinal Tract | 7 | 2019 | 187 | 1.690 |
Why?
|
| Hypersensitivity | 12 | 2022 | 249 | 1.550 |
Why?
|
| Humans | 259 | 2025 | 129847 | 1.520 |
Why?
|
| Endoscopy, Gastrointestinal | 16 | 2024 | 219 | 1.480 |
Why?
|
| Gastroenterology | 4 | 2023 | 177 | 1.420 |
Why?
|
| Anti-Inflammatory Agents | 13 | 2019 | 482 | 1.300 |
Why?
|
| Microbiota | 5 | 2022 | 734 | 1.240 |
Why?
|
| Inflammatory Bowel Diseases | 7 | 2022 | 326 | 1.200 |
Why?
|
| Esophageal Mucosa | 4 | 2024 | 19 | 1.160 |
Why?
|
| Adolescent | 74 | 2024 | 20451 | 1.140 |
Why?
|
| Gastroenteritis | 7 | 2023 | 67 | 1.110 |
Why?
|
| Child, Preschool | 55 | 2024 | 10522 | 1.080 |
Why?
|
| Endoscopy | 6 | 2023 | 290 | 0.980 |
Why?
|
| Mucous Membrane | 8 | 2023 | 125 | 0.980 |
Why?
|
| Severity of Illness Index | 16 | 2024 | 2739 | 0.920 |
Why?
|
| Tight Junctions | 4 | 2024 | 76 | 0.910 |
Why?
|
| Biopsy | 23 | 2024 | 1089 | 0.910 |
Why?
|
| Allergens | 10 | 2023 | 385 | 0.900 |
Why?
|
| Esophageal Stenosis | 8 | 2022 | 51 | 0.880 |
Why?
|
| Diet Therapy | 5 | 2018 | 34 | 0.870 |
Why?
|
| Leukocyte Count | 13 | 2024 | 326 | 0.870 |
Why?
|
| Quality of Life | 14 | 2024 | 2695 | 0.860 |
Why?
|
| Mast Cells | 12 | 2022 | 142 | 0.850 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 6 | 2024 | 274 | 0.820 |
Why?
|
| Male | 104 | 2024 | 63759 | 0.820 |
Why?
|
| Virtual Reality | 2 | 2021 | 53 | 0.820 |
Why?
|
| Adult | 70 | 2024 | 35634 | 0.800 |
Why?
|
| Interleukin-5 | 4 | 2014 | 45 | 0.780 |
Why?
|
| Adrenal Cortex Hormones | 9 | 2019 | 532 | 0.760 |
Why?
|
| Claudin-1 | 2 | 2019 | 15 | 0.760 |
Why?
|
| Glucocorticoids | 8 | 2023 | 582 | 0.750 |
Why?
|
| Female | 98 | 2024 | 68829 | 0.740 |
Why?
|
| Peanut Hypersensitivity | 7 | 2017 | 140 | 0.730 |
Why?
|
| Immunity, Mucosal | 3 | 2016 | 94 | 0.700 |
Why?
|
| Inflammation | 16 | 2024 | 2748 | 0.680 |
Why?
|
| Diagnosis, Differential | 21 | 2021 | 1434 | 0.680 |
Why?
|
| Dilatation | 9 | 2025 | 61 | 0.680 |
Why?
|
| Deglutition Disorders | 10 | 2023 | 133 | 0.670 |
Why?
|
| Collagen | 4 | 2015 | 438 | 0.670 |
Why?
|
| Colon | 7 | 2019 | 257 | 0.660 |
Why?
|
| GATA3 Transcription Factor | 3 | 2024 | 25 | 0.650 |
Why?
|
| Cytokines | 12 | 2020 | 2022 | 0.640 |
Why?
|
| Fibrosis | 5 | 2024 | 526 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 1368 | 0.630 |
Why?
|
| Prospective Studies | 21 | 2024 | 7158 | 0.620 |
Why?
|
| Animals | 57 | 2024 | 35409 | 0.610 |
Why?
|
| MicroRNAs | 5 | 2024 | 680 | 0.590 |
Why?
|
| Eosinophil Granule Proteins | 4 | 2012 | 21 | 0.590 |
Why?
|
| Crohn Disease | 4 | 2020 | 217 | 0.590 |
Why?
|
| Epithelium | 8 | 2023 | 311 | 0.590 |
Why?
|
| Diet | 7 | 2022 | 1212 | 0.580 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2013 | 1205 | 0.580 |
Why?
|
| Intestines | 7 | 2021 | 350 | 0.550 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2024 | 374 | 0.550 |
Why?
|
| Infant | 32 | 2024 | 9018 | 0.540 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2012 | 61 | 0.540 |
Why?
|
| Fluticasone | 7 | 2023 | 90 | 0.540 |
Why?
|
| Family | 5 | 2014 | 646 | 0.530 |
Why?
|
| Asthma | 8 | 2024 | 2225 | 0.530 |
Why?
|
| Endoscopy, Digestive System | 6 | 2021 | 123 | 0.530 |
Why?
|
| Receptors, CCR3 | 2 | 2018 | 8 | 0.520 |
Why?
|
| Arachis | 5 | 2017 | 109 | 0.520 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 4077 | 0.510 |
Why?
|
| Claudins | 3 | 2024 | 25 | 0.510 |
Why?
|
| Enterocolitis | 2 | 2013 | 17 | 0.510 |
Why?
|
| Probiotics | 1 | 2016 | 51 | 0.500 |
Why?
|
| Young Adult | 25 | 2024 | 12467 | 0.500 |
Why?
|
| Drug Discovery | 2 | 2017 | 131 | 0.490 |
Why?
|
| Th2 Cells | 5 | 2024 | 171 | 0.490 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2015 | 11 | 0.490 |
Why?
|
| Interleukin-33 | 1 | 2015 | 48 | 0.480 |
Why?
|
| Celiac Disease | 2 | 2015 | 286 | 0.470 |
Why?
|
| Peptides | 6 | 2018 | 926 | 0.470 |
Why?
|
| Administration, Oral | 5 | 2023 | 787 | 0.470 |
Why?
|
| Gastrointestinal Agents | 3 | 2019 | 60 | 0.470 |
Why?
|
| Biological Products | 3 | 2024 | 207 | 0.460 |
Why?
|
| Ileum | 1 | 2015 | 116 | 0.460 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2014 | 10 | 0.450 |
Why?
|
| Constipation | 2 | 2012 | 88 | 0.450 |
Why?
|
| Bottle Feeding | 1 | 2014 | 21 | 0.440 |
Why?
|
| Ileitis | 2 | 2011 | 32 | 0.440 |
Why?
|
| Signal Transduction | 9 | 2020 | 4935 | 0.440 |
Why?
|
| Interleukin-13 | 4 | 2021 | 147 | 0.440 |
Why?
|
| Retrospective Studies | 28 | 2024 | 14553 | 0.440 |
Why?
|
| Mice | 33 | 2024 | 16983 | 0.440 |
Why?
|
| Steroids | 5 | 2023 | 158 | 0.430 |
Why?
|
| Mice, Transgenic | 4 | 2024 | 2135 | 0.430 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2012 | 6 | 0.430 |
Why?
|
| Esophagitis, Peptic | 3 | 2006 | 15 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2023 | 756 | 0.420 |
Why?
|
| Algorithms | 7 | 2022 | 1617 | 0.410 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 266 | 0.410 |
Why?
|
| beta-Defensins | 1 | 2013 | 20 | 0.410 |
Why?
|
| Biomarkers | 10 | 2024 | 3971 | 0.400 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 133 | 0.400 |
Why?
|
| Mucositis | 1 | 2012 | 19 | 0.390 |
Why?
|
| Immunotherapy | 3 | 2020 | 596 | 0.390 |
Why?
|
| Biomedical Research | 5 | 2024 | 640 | 0.390 |
Why?
|
| Hypoxia-Inducible Factor 1 | 8 | 2020 | 72 | 0.380 |
Why?
|
| Rare Diseases | 1 | 2012 | 96 | 0.370 |
Why?
|
| Feeding Behavior | 5 | 2019 | 626 | 0.370 |
Why?
|
| Esophageal Diseases | 2 | 2008 | 27 | 0.370 |
Why?
|
| Neutrophils | 8 | 2017 | 1209 | 0.370 |
Why?
|
| Consensus | 8 | 2022 | 622 | 0.360 |
Why?
|
| Adrenal Insufficiency | 2 | 2022 | 32 | 0.360 |
Why?
|
| Eosinophil Peroxidase | 3 | 2018 | 6 | 0.360 |
Why?
|
| Chemokines, CC | 2 | 2001 | 33 | 0.350 |
Why?
|
| Nuclear Proteins | 6 | 2018 | 660 | 0.350 |
Why?
|
| Dermatitis, Atopic | 1 | 2014 | 319 | 0.340 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 9 | 2017 | 21 | 0.340 |
Why?
|
| Middle Aged | 28 | 2024 | 31177 | 0.340 |
Why?
|
| Cell Communication | 3 | 2017 | 301 | 0.340 |
Why?
|
| Myeloid Cells | 2 | 2024 | 142 | 0.340 |
Why?
|
| Breast Feeding | 1 | 2014 | 424 | 0.340 |
Why?
|
| Food | 3 | 2020 | 156 | 0.330 |
Why?
|
| Ribonucleases | 2 | 2000 | 54 | 0.320 |
Why?
|
| Androstadienes | 3 | 2014 | 106 | 0.320 |
Why?
|
| Blood Proteins | 3 | 2002 | 245 | 0.320 |
Why?
|
| Treatment Outcome | 18 | 2024 | 10241 | 0.320 |
Why?
|
| Cell Degranulation | 5 | 2020 | 42 | 0.320 |
Why?
|
| Interleukin-8 | 2 | 2000 | 264 | 0.320 |
Why?
|
| Dexamethasone | 7 | 2012 | 352 | 0.300 |
Why?
|
| United States | 27 | 2024 | 13913 | 0.300 |
Why?
|
| Diagnostic Techniques, Digestive System | 3 | 2018 | 12 | 0.300 |
Why?
|
| Th1 Cells | 2 | 2024 | 137 | 0.290 |
Why?
|
| Case-Control Studies | 9 | 2024 | 3384 | 0.290 |
Why?
|
| Immunoglobulin E | 8 | 2017 | 330 | 0.290 |
Why?
|
| Budesonide | 3 | 2022 | 89 | 0.290 |
Why?
|
| Age Factors | 9 | 2020 | 3161 | 0.290 |
Why?
|
| Patient Compliance | 1 | 2012 | 568 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1514 | 0.280 |
Why?
|
| Pregnenediones | 2 | 2021 | 20 | 0.280 |
Why?
|
| History, 20th Century | 3 | 2014 | 295 | 0.280 |
Why?
|
| Gene Expression Regulation | 9 | 2021 | 2545 | 0.280 |
Why?
|
| Fibroblasts | 3 | 2021 | 954 | 0.270 |
Why?
|
| Eosinophil Major Basic Protein | 2 | 2008 | 7 | 0.270 |
Why?
|
| Deglutition | 2 | 2019 | 67 | 0.270 |
Why?
|
| Predictive Value of Tests | 5 | 2025 | 1951 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 5468 | 0.260 |
Why?
|
| Chemokine CCL24 | 2 | 2019 | 11 | 0.260 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 5437 | 0.250 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 148 | 0.250 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 716 | 0.240 |
Why?
|
| Caco-2 Cells | 6 | 2012 | 76 | 0.240 |
Why?
|
| Keratins | 2 | 2024 | 175 | 0.240 |
Why?
|
| Milk Hypersensitivity | 2 | 2003 | 19 | 0.240 |
Why?
|
| Biological Assay | 1 | 2006 | 119 | 0.240 |
Why?
|
| Anti-Allergic Agents | 3 | 2015 | 45 | 0.230 |
Why?
|
| Endosonography | 2 | 2003 | 141 | 0.230 |
Why?
|
| Chemokines | 3 | 2024 | 227 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1201 | 0.220 |
Why?
|
| DNA-Binding Proteins | 5 | 2018 | 1441 | 0.220 |
Why?
|
| Duodenitis | 1 | 2024 | 7 | 0.220 |
Why?
|
| Neuropeptides | 2 | 2001 | 72 | 0.210 |
Why?
|
| Intestine, Small | 3 | 2019 | 151 | 0.210 |
Why?
|
| Cell Movement | 5 | 2018 | 950 | 0.210 |
Why?
|
| Baclofen | 1 | 2003 | 15 | 0.210 |
Why?
|
| Massage | 2 | 2014 | 43 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 188 | 0.210 |
Why?
|
| History, 21st Century | 2 | 2014 | 186 | 0.210 |
Why?
|
| Hypoxia | 4 | 2024 | 1087 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2017 | 1274 | 0.210 |
Why?
|
| Family Characteristics | 1 | 2024 | 180 | 0.200 |
Why?
|
| Milk Proteins | 1 | 2003 | 34 | 0.200 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 65 | 0.200 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 235 | 0.200 |
Why?
|
| Colitis, Microscopic | 1 | 2022 | 4 | 0.190 |
Why?
|
| Homeostasis | 3 | 2021 | 605 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2004 | 1645 | 0.190 |
Why?
|
| Cell Line, Transformed | 2 | 2019 | 139 | 0.190 |
Why?
|
| Self Report | 4 | 2024 | 800 | 0.190 |
Why?
|
| Tetraspanins | 1 | 2021 | 18 | 0.190 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 508 | 0.190 |
Why?
|
| Administration, Topical | 3 | 2020 | 147 | 0.190 |
Why?
|
| Phenotype | 7 | 2022 | 3062 | 0.180 |
Why?
|
| RNA, Messenger | 8 | 2018 | 2703 | 0.180 |
Why?
|
| Sex Chromosomes | 1 | 2021 | 50 | 0.180 |
Why?
|
| Disease Progression | 3 | 2024 | 2628 | 0.180 |
Why?
|
| Oxazolone | 2 | 2012 | 5 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2015 | 524 | 0.180 |
Why?
|
| Mice, Knockout | 7 | 2024 | 2888 | 0.180 |
Why?
|
| Chemokine CCL11 | 3 | 2011 | 26 | 0.180 |
Why?
|
| Infant, Newborn | 5 | 2023 | 5772 | 0.180 |
Why?
|
| Neutrophil Activation | 2 | 2003 | 80 | 0.180 |
Why?
|
| Aneuploidy | 1 | 2021 | 92 | 0.180 |
Why?
|
| Growth Substances | 1 | 2001 | 148 | 0.180 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2020 | 12 | 0.180 |
Why?
|
| Gene Expression | 6 | 2021 | 1465 | 0.170 |
Why?
|
| Mucins | 1 | 2001 | 70 | 0.170 |
Why?
|
| Genetic Loci | 2 | 2021 | 274 | 0.170 |
Why?
|
| Polysaccharide-Lyases | 1 | 2000 | 11 | 0.170 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2000 | 22 | 0.170 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 28 | 0.170 |
Why?
|
| Telemedicine | 2 | 2019 | 792 | 0.170 |
Why?
|
| Peroxidase | 2 | 2015 | 175 | 0.170 |
Why?
|
| Transition to Adult Care | 1 | 2021 | 82 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 253 | 0.170 |
Why?
|
| Esophageal Motility Disorders | 2 | 2011 | 26 | 0.170 |
Why?
|
| Anaphylaxis | 3 | 2011 | 99 | 0.170 |
Why?
|
| Dietary Exposure | 1 | 2019 | 5 | 0.170 |
Why?
|
| Skin Tests | 6 | 2017 | 100 | 0.160 |
Why?
|
| Chemokine CCL26 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 2 | 2024 | 173 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 2271 | 0.160 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 357 | 0.160 |
Why?
|
| Models, Biological | 2 | 2008 | 1724 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2001 | 222 | 0.160 |
Why?
|
| Nanoparticles | 3 | 2018 | 376 | 0.160 |
Why?
|
| Cell Hypoxia | 6 | 2004 | 234 | 0.160 |
Why?
|
| Macrophages | 2 | 2024 | 1489 | 0.160 |
Why?
|
| Gastrostomy | 2 | 2018 | 109 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2020 | 804 | 0.160 |
Why?
|
| Nutrition Therapy | 1 | 2019 | 32 | 0.150 |
Why?
|
| Penicillamine | 1 | 1998 | 23 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2024 | 1900 | 0.150 |
Why?
|
| Nutritional Status | 3 | 2018 | 328 | 0.150 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1998 | 15 | 0.150 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 186 | 0.150 |
Why?
|
| Feeding and Eating Disorders | 2 | 2018 | 147 | 0.150 |
Why?
|
| Integrins | 1 | 2019 | 94 | 0.150 |
Why?
|
| Protein Stability | 1 | 2019 | 162 | 0.150 |
Why?
|
| Abscess | 2 | 2012 | 73 | 0.150 |
Why?
|
| Time Factors | 5 | 2019 | 6550 | 0.150 |
Why?
|
| Nephrotic Syndrome | 1 | 1998 | 28 | 0.150 |
Why?
|
| Stem Cell Factor | 1 | 1998 | 14 | 0.150 |
Why?
|
| Chelating Agents | 1 | 1998 | 69 | 0.150 |
Why?
|
| Anxiety | 2 | 2017 | 976 | 0.150 |
Why?
|
| Radiography | 4 | 2015 | 800 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2018 | 30 | 0.150 |
Why?
|
| Arachidonic Acids | 1 | 1998 | 59 | 0.150 |
Why?
|
| Mice, Inbred Strains | 4 | 2011 | 408 | 0.150 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 44 | 0.150 |
Why?
|
| Population Groups | 1 | 2018 | 60 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 2018 | 32 | 0.140 |
Why?
|
| Permeability | 4 | 2011 | 158 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 1005 | 0.140 |
Why?
|
| Feasibility Studies | 2 | 2019 | 870 | 0.140 |
Why?
|
| Placebos | 1 | 2018 | 201 | 0.140 |
Why?
|
| Histological Techniques | 1 | 2018 | 40 | 0.140 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 65 | 0.140 |
Why?
|
| Eczema | 2 | 2017 | 67 | 0.140 |
Why?
|
| Cells, Cultured | 9 | 2017 | 4102 | 0.140 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1847 | 0.140 |
Why?
|
| Internet | 1 | 2022 | 620 | 0.140 |
Why?
|
| Prevalence | 5 | 2021 | 2564 | 0.140 |
Why?
|
| Cell Line | 7 | 2018 | 2780 | 0.140 |
Why?
|
| Prognosis | 4 | 2018 | 3773 | 0.130 |
Why?
|
| Anesthetics, Intravenous | 1 | 2017 | 46 | 0.130 |
Why?
|
| Parents | 3 | 2024 | 1319 | 0.130 |
Why?
|
| Medical History Taking | 2 | 2015 | 118 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2003 | 596 | 0.130 |
Why?
|
| Interdisciplinary Research | 1 | 2017 | 26 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 1368 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2008 | 541 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 2724 | 0.130 |
Why?
|
| Aged | 12 | 2021 | 22107 | 0.130 |
Why?
|
| Propofol | 1 | 2017 | 63 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 158 | 0.130 |
Why?
|
| Receptor, Adenosine A2B | 2 | 2015 | 43 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 298 | 0.130 |
Why?
|
| Dietetics | 2 | 2017 | 22 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 147 | 0.130 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2017 | 104 | 0.130 |
Why?
|
| Secale | 1 | 2015 | 1 | 0.130 |
Why?
|
| Hordeum | 1 | 2015 | 2 | 0.130 |
Why?
|
| Endothelial Cells | 1 | 2021 | 749 | 0.130 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 3089 | 0.130 |
Why?
|
| Triticum | 1 | 2015 | 11 | 0.130 |
Why?
|
| Gastroenterologists | 1 | 2016 | 18 | 0.130 |
Why?
|
| Serotonin | 1 | 1998 | 319 | 0.130 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2016 | 16 | 0.130 |
Why?
|
| Meals | 1 | 2017 | 119 | 0.130 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 149 | 0.120 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2016 | 58 | 0.120 |
Why?
|
| 5'-Nucleotidase | 2 | 2008 | 41 | 0.120 |
Why?
|
| Inflammasomes | 1 | 2017 | 126 | 0.120 |
Why?
|
| Dextran Sulfate | 3 | 2024 | 79 | 0.120 |
Why?
|
| Glutens | 1 | 2015 | 57 | 0.120 |
Why?
|
| Helminths | 1 | 2015 | 7 | 0.120 |
Why?
|
| Helminthiasis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2019 | 463 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 954 | 0.120 |
Why?
|
| Remission Induction | 4 | 2020 | 274 | 0.120 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 33 | 0.120 |
Why?
|
| Respiratory System | 1 | 2016 | 156 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 636 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2017 | 190 | 0.120 |
Why?
|
| Fibronectins | 1 | 2015 | 127 | 0.120 |
Why?
|
| Patient Preference | 2 | 2022 | 184 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 192 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 26 | 0.120 |
Why?
|
| Lung | 2 | 2018 | 3940 | 0.120 |
Why?
|
| Desmosomes | 1 | 2014 | 21 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2016 | 334 | 0.120 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 234 | 0.110 |
Why?
|
| Cost of Illness | 2 | 2014 | 277 | 0.110 |
Why?
|
| Calpain | 1 | 2014 | 57 | 0.110 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 207 | 0.110 |
Why?
|
| Allergy and Immunology | 3 | 2020 | 42 | 0.110 |
Why?
|
| HT29 Cells | 2 | 2012 | 36 | 0.110 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2014 | 64 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 280 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2014 | 59 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2019 | 561 | 0.110 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 38 | 0.110 |
Why?
|
| RNA, Bacterial | 1 | 2015 | 182 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1686 | 0.110 |
Why?
|
| Ileal Neoplasms | 1 | 1993 | 3 | 0.110 |
Why?
|
| Ileocecal Valve | 1 | 1993 | 4 | 0.110 |
Why?
|
| Twins, Dizygotic | 1 | 2014 | 181 | 0.110 |
Why?
|
| Symptom Assessment | 1 | 2015 | 125 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2018 | 509 | 0.110 |
Why?
|
| Intussusception | 1 | 1993 | 27 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 26 | 0.110 |
Why?
|
| Twins, Monozygotic | 1 | 2014 | 209 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 165 | 0.110 |
Why?
|
| Autophagy | 1 | 2016 | 266 | 0.100 |
Why?
|
| Immunoglobulin G | 3 | 2018 | 851 | 0.100 |
Why?
|
| Eosinophil Cationic Protein | 2 | 2012 | 10 | 0.100 |
Why?
|
| Electric Impedance | 3 | 2017 | 102 | 0.100 |
Why?
|
| Risk Factors | 7 | 2024 | 9801 | 0.100 |
Why?
|
| Polypharmacy | 1 | 2014 | 84 | 0.100 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 185 | 0.100 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2012 | 27 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 2016 | 0.100 |
Why?
|
| Calcium | 3 | 2012 | 1212 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2016 | 773 | 0.100 |
Why?
|
| Expressed Sequence Tags | 1 | 2012 | 40 | 0.100 |
Why?
|
| Lysophospholipase | 1 | 2012 | 10 | 0.100 |
Why?
|
| Cystic Fibrosis | 2 | 2021 | 1067 | 0.100 |
Why?
|
| Gastric Mucosa | 2 | 2011 | 53 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 583 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 355 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 505 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2013 | 166 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2017 | 356 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 151 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2017 | 641 | 0.100 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 159 | 0.100 |
Why?
|
| Food, Formulated | 2 | 2023 | 14 | 0.100 |
Why?
|
| Esophagogastric Junction | 2 | 2020 | 50 | 0.100 |
Why?
|
| Adaptation, Psychological | 2 | 2014 | 618 | 0.100 |
Why?
|
| Schools | 2 | 2013 | 443 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 184 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2012 | 92 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 157 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 329 | 0.090 |
Why?
|
| Eating | 1 | 2014 | 372 | 0.090 |
Why?
|
| Endpoint Determination | 2 | 2013 | 76 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 140 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 417 | 0.090 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 134 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2014 | 404 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2012 | 836 | 0.090 |
Why?
|
| Child Behavior | 1 | 2013 | 236 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 163 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 75 | 0.090 |
Why?
|
| Neutrophil Infiltration | 1 | 2011 | 105 | 0.090 |
Why?
|
| Switzerland | 3 | 2015 | 36 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 639 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2012 | 1716 | 0.090 |
Why?
|
| Antigens, CD1 | 2 | 2002 | 58 | 0.090 |
Why?
|
| Th1-Th2 Balance | 1 | 2010 | 8 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 813 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2019 | 1112 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 836 | 0.090 |
Why?
|
| Feeding and Eating Disorders of Childhood | 1 | 2010 | 7 | 0.090 |
Why?
|
| Equipment Design | 1 | 2012 | 514 | 0.090 |
Why?
|
| Cyclosporine | 3 | 1997 | 263 | 0.090 |
Why?
|
| Professional Role | 1 | 2012 | 158 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 918 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2012 | 338 | 0.080 |
Why?
|
| RNA, Small Interfering | 3 | 2021 | 590 | 0.080 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 255 | 0.080 |
Why?
|
| Caregivers | 1 | 2017 | 809 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2012 | 697 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 201 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 2 | 2012 | 462 | 0.080 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1989 | 2 | 0.080 |
Why?
|
| Esophageal pH Monitoring | 1 | 2009 | 23 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2012 | 592 | 0.080 |
Why?
|
| Foreign Bodies | 1 | 2011 | 103 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 778 | 0.080 |
Why?
|
| Manometry | 1 | 2009 | 92 | 0.080 |
Why?
|
| Health Status | 1 | 2014 | 758 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2017 | 1070 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 4896 | 0.080 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2020 | 5444 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 311 | 0.080 |
Why?
|
| Integrin beta1 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2014 | 1597 | 0.080 |
Why?
|
| Chemotactic Factors, Eosinophil | 2 | 2017 | 7 | 0.080 |
Why?
|
| Gastrectomy | 1 | 1989 | 102 | 0.080 |
Why?
|
| Diarrhea | 1 | 2010 | 181 | 0.080 |
Why?
|
| Advisory Committees | 2 | 2020 | 216 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2010 | 143 | 0.070 |
Why?
|
| Gastric Acidity Determination | 1 | 2008 | 7 | 0.070 |
Why?
|
| Gastric Acid | 1 | 2008 | 14 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 220 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2011 | 1724 | 0.070 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2008 | 21 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2009 | 222 | 0.070 |
Why?
|
| Paneth Cells | 1 | 2008 | 16 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1690 | 0.070 |
Why?
|
| Social Support | 1 | 2012 | 587 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2006 | 137 | 0.070 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 67 | 0.070 |
Why?
|
| Stomach | 2 | 2019 | 109 | 0.070 |
Why?
|
| Forecasting | 2 | 2019 | 361 | 0.070 |
Why?
|
| Eosinophil-Derived Neurotoxin | 2 | 2012 | 3 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 743 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2010 | 385 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 334 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2008 | 201 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2008 | 291 | 0.060 |
Why?
|
| Nutritional Support | 1 | 2006 | 32 | 0.060 |
Why?
|
| Wound Healing | 1 | 2008 | 308 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 2646 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2016 | 1160 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2007 | 204 | 0.060 |
Why?
|
| Gels | 1 | 2006 | 83 | 0.060 |
Why?
|
| Monocytes | 2 | 2020 | 554 | 0.060 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 12 | 0.060 |
Why?
|
| Disease Management | 2 | 2020 | 592 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 5085 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2008 | 386 | 0.060 |
Why?
|
| Azoxymethane | 1 | 2024 | 20 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2020 | 306 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 903 | 0.060 |
Why?
|
| Child Nutrition Disorders | 2 | 2018 | 20 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 1323 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 827 | 0.060 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2024 | 23 | 0.060 |
Why?
|
| Leukemic Infiltration | 1 | 2003 | 5 | 0.050 |
Why?
|
| Sigmoidoscopy | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2021 | 422 | 0.050 |
Why?
|
| T-Box Domain Proteins | 1 | 2024 | 96 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2003 | 26 | 0.050 |
Why?
|
| Thioguanine | 1 | 2003 | 18 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1119 | 0.050 |
Why?
|
| Breath Tests | 1 | 2024 | 87 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2003 | 22 | 0.050 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2003 | 27 | 0.050 |
Why?
|
| Cytarabine | 1 | 2003 | 57 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 82 | 0.050 |
Why?
|
| Pyrophosphatases | 1 | 2003 | 22 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2002 | 141 | 0.050 |
Why?
|
| Health Surveys | 2 | 2017 | 495 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2006 | 583 | 0.050 |
Why?
|
| Etoposide | 1 | 2003 | 148 | 0.050 |
Why?
|
| Physicians | 1 | 2012 | 875 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2511 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2024 | 214 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 29 | 0.050 |
Why?
|
| Glycolysis | 1 | 2024 | 314 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 123 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1311 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 127 | 0.050 |
Why?
|
| Pain | 2 | 2022 | 791 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 77 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 1326 | 0.050 |
Why?
|
| Antacids | 1 | 2001 | 16 | 0.050 |
Why?
|
| Adenosine | 1 | 2003 | 227 | 0.050 |
Why?
|
| Trefoil Factor-2 | 1 | 2001 | 3 | 0.050 |
Why?
|
| Trefoil Factor-3 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Fundoplication | 1 | 2001 | 54 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2001 | 84 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 53 | 0.040 |
Why?
|
| Myenteric Plexus | 1 | 2020 | 4 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 187 | 0.040 |
Why?
|
| Base Sequence | 3 | 2017 | 2142 | 0.040 |
Why?
|
| Rural Health | 1 | 2021 | 71 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 349 | 0.040 |
Why?
|
| Klinefelter Syndrome | 1 | 2021 | 56 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2000 | 36 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2003 | 377 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 205 | 0.040 |
Why?
|
| CD18 Antigens | 1 | 2000 | 26 | 0.040 |
Why?
|
| International Cooperation | 1 | 2021 | 177 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 190 | 0.040 |
Why?
|
| Recurrence | 1 | 2024 | 1013 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 2000 | 68 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2000 | 68 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 284 | 0.040 |
Why?
|
| Weight Gain | 2 | 2014 | 510 | 0.040 |
Why?
|
| Acute Disease | 2 | 2015 | 980 | 0.040 |
Why?
|
| HeLa Cells | 3 | 2008 | 611 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 1998 | 302 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 1973 | 0.040 |
Why?
|
| Dogs | 1 | 2001 | 385 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 46 | 0.040 |
Why?
|
| Erythema | 1 | 2019 | 28 | 0.040 |
Why?
|
| Ulcer | 1 | 2019 | 28 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2000 | 224 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 1999 | 42 | 0.040 |
Why?
|
| Amino Acids | 1 | 2023 | 487 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 160 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2021 | 163 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2021 | 170 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2020 | 133 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2002 | 834 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 483 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 122 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 1213 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 855 | 0.040 |
Why?
|
| Trientine | 1 | 1998 | 1 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 92 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 187 | 0.040 |
Why?
|
| Retreatment | 1 | 1998 | 70 | 0.040 |
Why?
|
| Cromolyn Sodium | 1 | 1998 | 11 | 0.040 |
Why?
|
| Organizations | 1 | 2018 | 22 | 0.040 |
Why?
|
| Ionophores | 1 | 1998 | 23 | 0.040 |
Why?
|
| Concanavalin A | 1 | 1998 | 75 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 97 | 0.040 |
Why?
|
| Edema | 1 | 1999 | 124 | 0.040 |
Why?
|
| Nutrition Assessment | 2 | 2010 | 86 | 0.040 |
Why?
|
| Histamine | 1 | 1998 | 65 | 0.040 |
Why?
|
| Models, Animal | 2 | 2016 | 376 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2018 | 59 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 1045 | 0.040 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2018 | 49 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1877 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1998 | 110 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1998 | 85 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 1058 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 71 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 122 | 0.040 |
Why?
|
| Lipids | 1 | 2002 | 628 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 174 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2018 | 30 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 162 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 366 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 1058 | 0.040 |
Why?
|
| RNA Transport | 1 | 2017 | 23 | 0.040 |
Why?
|
| Hirschsprung Disease | 1 | 1999 | 84 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 1999 | 304 | 0.040 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2017 | 6 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 175 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 158 | 0.030 |
Why?
|
| Skin Irritancy Tests | 1 | 2017 | 2 | 0.030 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2017 | 15 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 204 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 94 | 0.030 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 8 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2020 | 433 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 108 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2017 | 40 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2017 | 45 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 314 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 902 | 0.030 |
Why?
|
| Colorado | 2 | 2017 | 4410 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 185 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2009 | 1708 | 0.030 |
Why?
|
| Egg Hypersensitivity | 1 | 2017 | 26 | 0.030 |
Why?
|
| Nutritional Sciences | 1 | 2017 | 43 | 0.030 |
Why?
|
| Pentoxifylline | 1 | 1996 | 24 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 317 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2020 | 481 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 759 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2017 | 184 | 0.030 |
Why?
|
| Chloroquine | 1 | 2016 | 51 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 541 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 433 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2015 | 133 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 392 | 0.030 |
Why?
|
| Skin Diseases | 2 | 2012 | 143 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 1033 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 534 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 123 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 37 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 399 | 0.030 |
Why?
|
| Mouth | 1 | 2015 | 84 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 22 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 369 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 209 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 306 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 631 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 872 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2015 | 45 | 0.030 |
Why?
|
| Child Health Services | 1 | 2017 | 184 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1560 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 1248 | 0.030 |
Why?
|
| Proteins | 1 | 2000 | 944 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 814 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 244 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 146 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 1110 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1551 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 377 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2015 | 363 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 979 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2020 | 875 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 504 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 306 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2062 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1993 | 13 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1937 | 0.030 |
Why?
|
| Rats | 2 | 2002 | 5487 | 0.030 |
Why?
|
| Leukocytes | 1 | 1995 | 306 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 546 | 0.030 |
Why?
|
| Apyrase | 2 | 2003 | 16 | 0.030 |
Why?
|
| Appetite | 1 | 2013 | 61 | 0.030 |
Why?
|
| Neisseria meningitidis | 1 | 1993 | 23 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 441 | 0.030 |
Why?
|
| Meningococcal Infections | 1 | 1993 | 24 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1993 | 59 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2012 | 14 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 615 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1993 | 119 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 20 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1416 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 2 | 2003 | 161 | 0.020 |
Why?
|
| Sinusitis | 2 | 2012 | 211 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 234 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 2123 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 766 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1291 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 822 | 0.020 |
Why?
|
| Vimentin | 1 | 2012 | 51 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 486 | 0.020 |
Why?
|
| Netrin-1 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Pneumonia | 1 | 2017 | 619 | 0.020 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2011 | 30 | 0.020 |
Why?
|
| Heartburn | 1 | 2011 | 12 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 858 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 27 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 875 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 7066 | 0.020 |
Why?
|
| Food Labeling | 1 | 2011 | 14 | 0.020 |
Why?
|
| DNA Primers | 2 | 2003 | 508 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 149 | 0.020 |
Why?
|
| Rhinitis | 1 | 2012 | 152 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 647 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2003 | 487 | 0.020 |
Why?
|
| Sputum | 1 | 2012 | 302 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 593 | 0.020 |
Why?
|
| Caseins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 11 | 0.020 |
Why?
|
| Emergencies | 1 | 2011 | 156 | 0.020 |
Why?
|
| Colistin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 233 | 0.020 |
Why?
|
| Diet, Gluten-Free | 1 | 2010 | 42 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 298 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 46 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 646 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 1264 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 673 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 264 | 0.020 |
Why?
|
| Mitochondrial Diseases | 1 | 2010 | 90 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 24 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 143 | 0.020 |
Why?
|
| Vancomycin | 1 | 2009 | 78 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 228 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 507 | 0.020 |
Why?
|
| Child Behavior Disorders | 1 | 2010 | 136 | 0.020 |
Why?
|
| Physical Examination | 1 | 2010 | 234 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 129 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 689 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2010 | 349 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3269 | 0.020 |
Why?
|
| Nasal Polyps | 1 | 1987 | 59 | 0.020 |
Why?
|
| Health Education | 1 | 2010 | 335 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 740 | 0.020 |
Why?
|
| Zebrafish | 1 | 2009 | 460 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2010 | 603 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 266 | 0.010 |
Why?
|
| Health Personnel | 1 | 2010 | 658 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 189 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2003 | 82 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 186 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 145 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 380 | 0.010 |
Why?
|
| Lactase-Phlorizin Hydrolase | 1 | 2002 | 2 | 0.010 |
Why?
|
| Lactase | 1 | 2002 | 2 | 0.010 |
Why?
|
| Passive Cutaneous Anaphylaxis | 1 | 2002 | 6 | 0.010 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2002 | 77 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 3185 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 2378 | 0.010 |
Why?
|
| Salmonella typhimurium | 1 | 2002 | 174 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 741 | 0.010 |
Why?
|
| Protein Transport | 1 | 2002 | 429 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 672 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2008 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2000 | 149 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 1645 | 0.010 |
Why?
|
| Antigens, CD1d | 1 | 1999 | 66 | 0.010 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 1999 | 4 | 0.010 |
Why?
|
| Ear | 1 | 1999 | 31 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 761 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 1999 | 15 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1999 | 269 | 0.010 |
Why?
|
| Tyrosine | 1 | 1999 | 223 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1999 | 141 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1999 | 207 | 0.010 |
Why?
|
| Enema | 1 | 1999 | 43 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 734 | 0.010 |
Why?
|
| Milk | 1 | 1999 | 122 | 0.010 |
Why?
|
| Rectum | 1 | 1999 | 170 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1999 | 326 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2057 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 1996 | 31 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1996 | 28 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 1996 | 44 | 0.010 |
Why?
|
| Contrast Media | 1 | 1999 | 394 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 2489 | 0.010 |
Why?
|
| Cell Count | 1 | 1996 | 318 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1995 | 370 | 0.010 |
Why?
|
| Cefuroxime | 1 | 1993 | 4 | 0.010 |
Why?
|
| Serotyping | 1 | 1993 | 28 | 0.010 |
Why?
|
| Eye Infections, Bacterial | 1 | 1993 | 27 | 0.010 |
Why?
|
| Cellulitis | 1 | 1993 | 49 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 338 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1993 | 306 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 310 | 0.010 |
Why?
|
| Bacteremia | 1 | 1993 | 194 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 725 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1987 | 154 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1987 | 957 | 0.000 |
Why?
|